The liver, a vital organ responsible for metabolism, detoxification, and protein synthesis, is notoriously susceptible to toxic insults from diverse substances. Traditional models for studying hepatotoxicity often rely on in vitro hepatocyte monocultures or animal models that fail to replicate the complex cellular heterogeneity and intercellular communication found in the human liver. This limitation has significantly hindered our understanding of indirect liver injury mechanisms, where parenchymal cells may be affected not by direct toxic insult but via signaling molecules derived from other liver cell types.

To address these challenges, researchers led by Sun, Zhang, and Niu have engineered multi-lineage hepatic organoids that closely mimic the architectural and functional complexity of human liver tissue. These organoids incorporate hepatocytes alongside key non-parenchymal cell populations, including hepatic stellate cells, Kupffer cells, and liver sinusoidal endothelial cells. This cellular diversity is critical, as it recapitulates the intricate cellular crosstalk that governs liver homeostasis, inflammatory responses, and injury repair mechanisms.

One of the study’s most striking revelations is the role of exosomes—small extracellular vesicles secreted by cells—in mediating indirect hepatotoxicity. Exosomes serve as vehicles for shuttling bioactive molecules such as lipids, proteins, and nucleic acids between cells, influencing recipient cell behavior. By leveraging their multi-lineage organoids, the researchers demonstrated that toxic compounds do not always induce liver damage via direct hepatocyte toxicity; instead, these compounds can trigger non-parenchymal cells to release exosomes laden with harmful cargo that subsequently induce hepatocyte injury.

The team meticulously characterized the exosomal content released following exposure to known hepatotoxic agents. Proteomic and transcriptomic analyses revealed enrichment of inflammatory mediators, oxidative stress-inducing factors, and pro-apoptotic signals in these vesicles. Functional assays confirmed that when these toxic exosomes were introduced into naïve hepatocytes, they precipitated mitochondrial dysfunction, enhanced reactive oxygen species (ROS) generation, and activation of apoptotic pathways, cumulatively culminating in cell death.

This exosome-mediated indirect mode of hepatotoxicity provides a plausible explanation for the often-observed discrepancies between in vitro assessments based solely on hepatocyte responses and the more complex clinical presentations of liver injury. It also raises critical considerations for drug development, highlighting that evaluating hepatotoxic risk requires an integrated model that includes non-parenchymal contributions and intercellular communication networks within the hepatic microenvironment.

Beyond elucidating this novel mechanism, the multi-lineage hepatic organoids demonstrated remarkable reproducibility and physiological relevance in modeling liver function, including bile acid metabolism, cytochrome P450 enzyme activity, and lipid handling. These functionalities underscore the organoids’ utility as a high-fidelity platform for pharmacological screening, toxicology assays, and mechanistic studies of liver disease pathogenesis.

Moreover, the application of multi-lineage organoids facilitates the investigation of chronic liver conditions wherein immune-mediated damage and fibrosis are orchestrated by complex cellular interactions. The presence of stellate cells and Kupffer cells enables probing the crosstalk underlying fibrogenesis and inflammatory milieu, advancing our capacity to study multifactorial liver disorders in a controlled, human-relevant setting.

Importantly, the study’s insights into exosome biology open avenues for therapeutic intervention. Targeting the biogenesis, release, or uptake of toxic exosomes could mitigate indirect hepatocyte injury and improve liver preservation during drug therapy or toxin exposure. Furthermore, exosomal cargo profiling could serve as a sensitive biomarker for the early detection of liver injury, enabling preemptive clinical management and individualized treatment regimens.

As the pharmaceutical industry grapples with the high attrition rates linked to hepatotoxicity during drug development, this research offers a compelling argument for integrating complex organoid systems into preclinical testing paradigms. By simulating human liver physiology with unprecedented fidelity, such models hold promise in enhancing predictive accuracy, reducing reliance on animal models, and accelerating the pipeline of safe and effective therapeutics.

The findings also resonate with the broader field of extracellular vesicle research, which is rapidly expanding our understanding of cell-to-cell communication in health and disease. The demonstration that exosomes can mediate drug-induced organ toxicity elevates their significance from mere biomarkers to active participants in pathological processes, warranting deeper exploration across various organ systems and disease modalities.

In conclusion, Sun, Zhang, Niu, and colleagues have delivered a landmark contribution by delineating a toxic exosome-mediated indirect hepatotoxicity pathway using cutting-edge multi-lineage hepatic organoids. This innovative approach not only enlightens fundamental liver biology and toxicology but also catalyzes the evolution of more sophisticated in vitro platforms that better recapitulate human physiology and pathology. As this field advances, such organoid models are poised to redefine precision medicine strategies and revolutionize safety assessment in drug development.

This pioneering work lays a robust foundation for future explorations of intercellular vesicular communication in liver diseases and invites integration with emerging technologies such as single-cell sequencing, spatial transcriptomics, and artificial intelligence-driven image analysis. Together, these advancements will chart a path toward deeper mechanistic insights and novel therapeutic targets, ultimately reducing the global burden of liver injury and enhancing patient outcomes worldwide.

Subject of Research: Multi-lineage hepatic organoids and toxic exosome-mediated indirect hepatotoxicity

Article Title: Multi-lineage hepatic organoids reveal toxic exosome mediated indirect hepatotoxicity

Article References:
Sun, L., Zhang, Y., Niu, Y. et al. Multi-lineage hepatic organoids reveal toxic exosome mediated indirect hepatotoxicity.
Nat Commun (2026). https://doi.org/10.1038/s41467-026-69548-0

Image Credits: AI Generated

One of the long-standing challenges in hepatology and tissue engineering has been the liver’s exceptional complexity. Unlike many organs, the liver performs a vast repertoire of bioactive and metabolic processes, from glucose regulation to bile acid secretion. Replicating this multifaceted functionality in vitro has been hindered by the liver’s demanding energy requirements and the difficulty of sustaining hepatocyte function. Typically, isolated hepatocytes undergo phenotypic changes rapidly when cultured, often transdifferentiating into cholangiocyte-like cells that line bile ducts, resulting in loss of the hepatocyte’s intrinsic metabolic capabilities within one to two weeks.

The innovative research team, led by Ryo Igarashi and Mayumi Oda, overcame this barrier by utilizing cryopreserved adult human hepatocytes sourced directly from patients. Their pivotal discovery centered on the application of oncostatin M, a cytokine involved in inflammatory signaling pathways that had not previously been leveraged in organoid culture systems. Treatment with oncostatin M triggered an extraordinary proliferation phase, achieving a million-fold expansion in organoid numbers. This unprecedented growth contrasts starkly with previous methodologies, which struggled to maintain viable hepatocyte populations beyond short timeframes.

Extended cultivation saw these hepatocyte organoids maintain their viability and proliferative capacity for over three months, surviving up to six months without losing the potential to differentiate. This longevity is critical, as it allows researchers to conduct extended functional studies and disease modeling that were previously impossible due to rapid cell decline. The team also pioneered a chemically-defined hormonal differentiation protocol that stimulates hepatocyte maturation. Post differentiation, the organoids began expressing key liver functions, including the synthesis and secretion of glucose, urea, cholesterol, triglycerides, and bile acids—broadcasting a level of metabolic activity comparable to in vivo human hepatocytes.

Particularly notable was the organoids’ formation of bile canaliculi-like networks—microscopic tubular structures that enable the transport of bile acids—mimicking the liver’s native architecture. This functionality is essential for modeling hepatobiliary diseases and evaluating drugs that target bile acid metabolism. Levels of albumin secretion, an essential plasma protein responsible for maintaining oncotic pressure and transporting various substances, not only matched but surpassed those reported in existing hepatocyte culture systems.

The identification of oncostatin M as a key modulator of hepatocyte proliferation represents more than just a technical milestone; it uncovers new molecular underpinnings of liver biology. According to senior researcher Toshiro Sato, this discovery expands the compendium of factors capable of ‘unlocking’ the regenerative and differentiation potential of adult liver cells. Previously, only a handful of molecules were known to induce organoid growth, but oncostatin M provides a novel avenue for the creation of diverse, functional liver tissue models.

The translation of this technology into preclinical models further demonstrated its therapeutic promise. When transplanted into immunocompromised mice with impaired liver function, the human hepatocyte organoids engrafted successfully, replacing lost liver cells and restoring fundamental liver functionalities. This achievement addresses the critical bottleneck in liver transplantation—the scarcity and fragility of donor organs. Unlike donated whole organs that must be transplanted rapidly post-harvest, hepatocyte organoids derived from frozen cells can potentially be expanded on demand, circumventing logistical and preservation challenges.

Moreover, this method may revolutionize regenerative therapies by enabling the generation of large quantities of functional liver tissue. Sato emphasizes that scaling up organoid proliferation to match the size and metabolic demand of a human liver remains a formidable hurdle but one with transformative potential. Should this be realized, it could redefine transplantation medicine, offering new lifelines to patients suffering from end-stage liver disease or genetic hepatic disorders.

Beyond transplantation, the hepatocyte organoids hold immense promise for pharmaceutical research. Traditional drug toxicity assessments rely on freshly isolated human hepatocytes, which lose functionality rapidly and vary considerably between batches. This variability complicates the development pipeline and inflates costs due to inconsistent experimental outcomes. In contrast, organoids provide a renewable, consistent source of metabolically active human liver cells, enabling more reliable drug screening, especially for hepatotoxic compounds.

The organoids have also proven superior in disease modeling. For example, they intrinsically synthesized lipids and, upon administration of therapeutic agents targeting metabolic-associated steatotic liver disease (MASLD), these lipid stores diminished accordingly. This contrasts with previous studies that introduced lipids artificially, offering less physiologically relevant models. Moreover, the team successfully employed gene-editing techniques to replicate pathological states such as ornithine transcarbamylase (OTC) deficiency—a rare, inherited disorder disrupting the urea cycle—thereby modeling genetic liver diseases with unprecedented fidelity.

Looking forward, researchers recognize the importance of enhancing organoid complexity. Incorporating additional liver cell types, such as Kupffer cells (resident macrophages), liver sinusoidal endothelial cells, and hepatic stellate cells, is vital to recapitulate the full cellular interplay that underpins liver physiology and immune responses. Furthermore, intensifying proliferative capacity beyond current levels remains a priority to meet the substantial cellular quantities demanded in clinical applications.

In sum, this innovative study represents a significant stride toward mimicking the human liver’s complexity in a laboratory platform. By integrating novel cytokine signaling pathways, advanced differentiation protocols, and precise gene editing, the researchers at Keio University have opened new horizons in personalized medicine, drug discovery, and regenerative therapies. As liver diseases continue to impose a global health burden, such cutting-edge organoid models may soon become indispensable tools in both basic science and translational medicine.

Subject of Research: Cells
Article Title: Generation of human adult hepatocyte organoids with metabolic functions
News Publication Date: April 16, 2025
Web References: http://dx.doi.org/10.1038/s41586-025-08861-y
Image Credits: Toshiro Sato from Keio University
Keywords: hepatocyte organoids, liver regeneration, oncostatin M, organoid proliferation, metabolic functions, liver disease modeling, MASLD, gene editing, urea cycle disorder, transplantation, regenerative medicine